• Profile
Close

Systematic review with meta-analysis: The effectiveness of either ustekinumab or vedolizumab in patients with Crohn disease refractory to anti-tumour necrosis factor

Alimentary Pharmacology and Therapeutics Dec 06, 2021

Parrot L, Dong C, Carbonnel F, et al. - Among patients suffering from Crohn disease (CD) refractory to anti-tumor necrosis factor (TNF), similar effectiveness of ustekinumab and vedolizumab in induction was evident in this study, however, maintenance with ustekinumab seemed to be more effective than with vedolizumab.

  • This is a systematic review and meta-analysis of five studies (four were retrospective and one was prospective) that compared ustekinumab and vedolizumab in patients with CD refractory to anti-TNF (of 1026 patients, 659 treated with ustekinumab and 367 received vedolizumab).

  • At week 14, there were similar outcomes in terms of clinical remission (odds ratios OR, 1.36), steroid-free clinical remission (OR 1.24) and biological remission (OR 0.80) rates between the two treatments.

  • At week 52, higher rates of clinical remission (OR 1.87), steroid-free clinical remission (OR 1.56), biological remission (OR 1.86) and treatment persistence (OR 2.37) were achieved with ustekinumab.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay